Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Cutler, Dorsey, Rijnbrand take on corporate affairs, chemistry and biology
March 18, 2015
By: Kristin Brooks
Managing Editor, Contract Pharma
Tekmira Pharmaceuticals has made executive appointments to its senior leadership team. Adam Cutler has been named senior vice president, corporate affairs; Dr. Bruce Dorsey has been appointed vice president, chemistry; and Dr. Rene Cornelis Rijnbrand has been named vice president, Biology. “We are delighted to welcome Adam, Bruce and Rene to our executive team at this exciting time in Tekmira’s evolution and emergence as an HBV solutions company,” said Dr. Mark J. Murray, Tekmira’s president and chief executive officer. “Adam has an unparalleled reputation as a top-ranked biotechnology sell-side analyst and advisor, with extensive experience in capital formation, corporate positioning and reputation management. Bruce and Rene each has more than 10 years of experience in the biopharmaceutical industry, leading high-profile discovery research teams spanning multiple therapeutic areas, with strong focus on virology and HBV.” Mr. Cutler joins the company from The Trout Group LLC, where he successfully executed financings and advised a wide range of life science companies on investor relations, business development, and capital raising strategy. He also spent 12 years as a sell-side analyst with firms including Credit Suisse, Canaccord Genuity, JMP Securities, and Banc of America Securities. Dr. Dorsey was most recently vice president, Chemistry with OnCore Biopharma, focusing on HBV and building the company’s U.S. operations. Previously, he held senior-level positions with Teva Pharmaceuticals, Cephalon, Locus Discovery and Merck & Co., where his therapeutic focus included virology, oncology, CNS, inflammatory and gastrointestinal disorders, and pain. Dr. Rijnbrand most recently served as vice president and head of Biology at OnCore Biopharma, where he led efforts in virology and immunology to develop curative approaches for chronic HBV infections. Previously, he directed the virology program at Vertex Pharmaceuticals and at Immusol/Itherex Pharmaceuticals.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !